Core Concepts
Anti-arrhythmic drugs pose risks of syncope and bradycardia in AF patients.
Abstract
The study highlights the risks associated with anti-arrhythmic drugs in treating atrial fibrillation (AF). Researchers analyzed data from 674,303 patients with new-onset AF, finding a threefold increased risk for syncope and pacemaker implantation in those prescribed anti-arrhythmic drugs. The risk was higher in older patients and women. The study emphasizes the need for careful evaluation before prescribing these drugs for AF. The findings suggest that bradyarrhythmia events are relatively infrequent but more common in patients on anti-arrhythmic drugs. The study raises questions about extended monitoring for patients on long-term anti-arrhythmic drugs. Limitations include the study's exclusive focus on a Korean population and the lack of detailed patient information due to the nature of the database used.
Stats
Anti-arrhythmic drugs associated with a 3.5 times increased risk for pacemaker implantation or syncope.
Use of anti-arrhythmic drugs linked to a twofold increased risk for syncope and a fivefold increased risk for pacemaker implantation.
Quotes
"This association of bradycardia with anti-arrhythmic drugs is not in itself a new observation." - Sanjay Dixit